Compare ARK Genomic Revolution ETF (ARKG) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs T-Mobile Us Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while T-Mobile Us Inc trades at $188.87 (market cap $203.03B). The key difference: T-Mobile Us Inc pays a 2.17% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, T-Mobile Us Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | TMUS | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $259.01 |
52-Week Low | $23.09 | $167.65 |
Market Cap | — | $203.03B |
Enterprise Value | — | $320.73B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
T-Mobile US (TMUS) trades at $187.61, up 3.38% on the day, with a neutral technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B, net income of $10.99B, and consistent cash flow generation. Recent leadership changes and competitive threats from SpaceX's potential market entry are key developments. Valuation metrics include a P/E of 19.94 and P/S of 2.32, while the consensus price target is $244.50, suggesting significant upside potential.
The outlook for TMUS is positive due to strong earnings beats, healthy profitability margins, and growth in postpaid accounts. Risks include rising debt levels, intense competition, and capital expenditure pressures. With 83% of analysts rating it a Buy, the stock presents a compelling opportunity for long-term investors, though monitoring competitive dynamics and interest expense trends is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
